Not Enough Evidence to Balance Harms, Benefit of Visual Skin Cancer Exam
There is currently not enough evidence to assess the balance of benefits and harms of a visual skin examination by a clinician to screen for skin cancer in asymptomatic adults. (Source: CancerNetwork)
Source: CancerNetwork - July 29, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Skin Cancer (Nonmelanoma) Source Type: news

Does Smoking Make You Look Older
Research shows smokers more susceptible to non-melanoma skin cancers, wrinkles, skin aging, psoriasis, dental problems and hair loss (Source: Disabled World)
Source: Disabled World - July 20, 2016 Category: Disability Tags: Dermatology Source Type: news

15, 30, 50, 70... Which SPF Should I Use?
By GalTime.com Seems like you need a PhD in SPF these days to understand what's on the label of most sunscreens. And believe you me, you want to make sure you have the right sunscreen slathered on your body before you hit the beach! Non-melanoma skin cancer is now the most common type of cancer in America. More than 3.5 million cases are reported annually... and that's just the reported cases. Many patients are treated in the doctor's office and a good number of those aren't included in the count. That's why the Archives of Dermatology recently called non-melanoma skin cancer an "under-recognized epidemic" in the U.S. O...
Source: Healthy Living - The Huffington Post - July 19, 2016 Category: Consumer Health News Source Type: news

Many skin cancer patients still too likely to sunburn
A recent study concludes that a substantial number of people with a history of the most frequent kind of nonmelanoma skin cancers still get sunburned at the same rate as those without previous history, probably because they are not using sun-protective methods the right way or in the right amounts. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 19, 2016 Category: Science Source Type: news

Many skin cancer patients still too likely to sunburn
(Johns Hopkins Medicine) A recent study by researchers at Johns Hopkins concludes that a substantial number of people with a history of the most frequent kind of nonmelanoma skin cancers still get sunburned at the same rate as those without previous history, probably because they are not using sun-protective methods the right way or in the right amounts. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2016 Category: Cancer & Oncology Source Type: news

'Secret ginger gene' may increase skin cancer risk for millions
Conclusion The study adds more weight to the importance of using sun protection to avoid skin cancer. We already know that people with red hair and freckles who burn easily are at increased risk of skin cancer. This study suggests other people may also have a higher risk, without knowing it. Taking sensible sun protection measures makes good sense for everyone. The findings are also useful for researchers, as they add to our understanding about how certain genetic traits affect the development of skin cancer. If DNA repair is reduced in people with some gene variants, sun damage may not be the only thing affecting their ...
Source: NHS News Feed - July 13, 2016 Category: Consumer Health News Tags: Cancer Genetics/stem cells Source Type: news

Everything You Need To Know About Choosing The Best Sunscreen
Fourth of July weekend is upon us, and along with barbecue equipment, beach toys and sandals, don't forget to stock up on some sunscreen for the holiday. Sun damage is responsible for 90 percent of nonmelanoma skin cancers in the United States, itself the most common form of cancer in the country, according to the Skin Cancer Foundation. In fact, more than 3.3 million people are diagnosed with skin cancer in the U.S. each year. The Food and Drug Administration recommends that consumers look for three things in their sunscreen: a "sun protection factor" (SPF) of 15 or more, "broad spectrum" protection and water resis...
Source: Healthy Living - The Huffington Post - July 1, 2016 Category: Consumer Health News Source Type: news

Sensus Healthcare closes $11m IPO
Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non-mel...
Source: Mass Device - June 8, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news

Sensus Healthcare prices $11m IPO
Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-e...
Source: Mass Device - June 3, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 16, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Otsuka gets in on ReCor Medical’s Paradise renal denervation device ReCor Medical said it landed a strategic investment from Japanese conglomerate Otsuka Pharmaceutical that will bring to Asia its Paradise renal denervation d...
Source: Mass Device - May 16, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news

Sensus Healthcare scales back planned IPO
Sensus Healthcare last week said it plans to scale back its planned initial public offering, after tabling the flotation earlier this year. Boca Raton, Fla.-based Sensus makes the SRT-100 and SRT-100 Vision photon X-ray low-energy superficial radiotherapy systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. Later that month, Sensus postponed the IPO. But in a May 13 regulatory filing, Sensus sai...
Source: Mass Device - May 16, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Oncology Radiosurgery Sensus Healthcare LLC Source Type: news

Search is on for cases of aggressive, ruxolitinib-associated skin cancers
ORLANDO – The hematologic cancer drug ruxolitinib seems to be associated with cases of aggressive nonmelanoma skin cancer. After treating a very aggressive squamous cell carcinoma in a 55-year-old man treated with ruxolitinib for polycythemia vera, and hearing firsthand of three other similar... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 30, 2016 Category: Dermatology Source Type: news

Sensus Healthcare postpones IPO
Sensus Healthcare reportedly postponed its initial public offering today, after setting terms earlier this month with a midpoint raise of $20 million. Boca Raton, Fla.-based Sensus makes the SRT-100 and SRT-100 Vision photon X-ray low-energy superficial radiotherapy systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. A mere 8 IPOs have priced in 2016, all in the healthcare sector, according t...
Source: Mass Device - March 30, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Dermatology Sensus Healthcare LLC Source Type: news